ReviewHepatology communications2026
The global burden of metabolic and alcohol-associated liver disease (MetALD).
Review in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Chronic liver disease is a leading cause of global morbidity and mortality, with an evolving etiologic landscape driven by rising metabolic dysfunction and persistent alcohol use. The introduction of metabolic and alcohol-associated liver disease (MetALD) recognizes the coexistence of these exposures as dual drivers of liver-related outcomes as a distinct clinical entity. This review synthesizes current evidence on the global epidemiology, clinical outcomes, and public health implications of MetALD. Current evidence suggests that ~10%-20% of individuals worldwide with hepatic steatosis meet criteria for MetALD. Emerging data demonstrate that the combination of cardiometabolic risk factors and alcohol is associated with more aggressive liver disease, including accelerated fibrosis progression, increased risk of cirrhosis and hepatic decompensation, and higher incidence of hepatocellular carcinoma compared with either exposure alone. In addition to major adverse liver outcomes, individuals with MetALD experience increased all-cause mortality, reflecting both progressive liver disease and the systemic effects of metabolic dysfunction and alcohol use. These factors contribute substantially to global disability-adjusted life years, particularly among working-age populations. The burden of MetALD varies across regions, reflecting differences in metabolic risk, alcohol consumption, and socioeconomic determinants, and is expected to rise further in both high- and middle-income settings. Despite its growing clinical relevance, the global burden of MetALD remains incompletely characterized due to limitations in standardized definitions, data availability, and ascertainment of alcohol use. Improved recognition, harmonized definitions, and integrated clinical and public health strategies are essential to better characterize and mitigate its impact on global liver health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.